Drug General Information (ID: DDILU3XEHP)
Drug Name			Ticlopidine		Drug Info		Heparin		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Fibrinolytic Agents				Anticoagulants
Structure

Mechanism of Ticlopidine-Heparin Interaction (Severity Level: Moderate)
Increased risk of bleeding Click to Show/Hide Mechanism Graph
Drug Name		Ticlopidine				Heparin
Mechanism		Risk of bleeding Antiplatelet				Risk of bleeding Anticoagulant
Key Mechanism Factor 1
		Factor Name		Bleeding
		Factor Description		Patients may be at risk for bleeding when the outcome of a disease or disease treatment confounds the standard mechanisms for maintaining hemostasis. Signs or symptoms of abnormal bleeding include: bleeding that takes a long time to stop (including nosebleeds, bleeding gums, bleeding from cuts and abrasions, and menstrual bleeding); severe unexplained bruising, or bruising that becomes larger; blood in the urine or stool, etc.
Mechanism Description		Increased risk of bleeding by the combination of Ticlopidine and Heparin

Recommended Action
Management		The manufacturer recommends that heparin be discontinued before initiating ticlopidine therapy. Patients who are to receive these drugs concomitantly should be closely monitored for signs of bleeding. Clinical trials have reported the concomitant use of heparin and ticlopidine in patients undergoing coronary stenting.

References
1	Product Information. Ticlid (ticlopidine). Syntex Laboratories Inc, Palo Alto, CA.